| Website | alvinepharma.com |
| Category | BioTech |
| Phone | (650) 632-1645 |
| Employees | |
| Description | biopharmaceutical company |
| Total | $29.5M |
| Series A, 9/06 Prospect Venture Partners Sofinnova Ventures | $8M |
| Series A, 9/09 Panorama Capital InterWest Partners Prospect Venture Partners Sofinnova Ventures Black River Asset Management Flagship Ventures | $21.5M |
Alvine Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing therapeutics for autoimmune/gastrointestinal diseases. Alvine’s lead product candidate, ALV003, is a combination protease engineered to digest gluten. It is being developed to treat patients with celiac disease.
